QYUNS-B (02509): QX030N/CLD-423 Completes First Dosing in Phase I Trial; Caldera Therapeutics Raises $112.5M

Stock News01-14

QYUNS-B (02509) announced that the Phase I clinical trial of its bispecific antibody, QX030N/CLD-423, which targets the clinically validated IL-23p19 and TL1A pathways, has successfully administered the first dose to healthy volunteers. As of the date of this announcement, the company's partner for QX030N/CLD-423, Caldera Therapeutics, Inc., has completed a cumulative financing round totaling $112.5 million. In April 2025, Caldera Therapeutics secured a $75 million Series A financing from Atlas Venture, LAV, and venBio, and recently completed a $37.5 million Series A-1 round led by Omega Funds, with participation from new investors including Wellington Management and Janus Henderson Investors.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1143628481?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-14 22:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1143628481","market":"sh","top_or_hot":-1,"title":"QYUNS-B (02509): QX030N/CLD-423 Completes First Dosing in Phase I Trial; Caldera Therapeutics Raises $112.5M","media":"Stock News","content":"<p>QYUNS-B (02509) announced that the Phase I clinical trial of its bispecific antibody, QX030N/CLD-423, which targets the clinically validated IL-23p19 and TL1A pathways, has successfully administered the first dose to healthy volunteers.\nAs of the date of this announcement, the company's partner for QX030N/CLD-423, Caldera Therapeutics, Inc., has completed a cumulative financing round totaling $112.5 million.\nIn April 2025, Caldera Therapeutics secured a $75 million Series A financing from Atlas Venture, LAV, and venBio, and recently completed a $37.5 million Series A-1 round led by Omega Funds, with participation from new investors including Wellington Management and Janus Henderson Investors.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>QYUNS-B (02509): QX030N/CLD-423 Completes First Dosing in Phase I Trial; Caldera Therapeutics Raises $112.5M</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nQYUNS-B (02509): QX030N/CLD-423 Completes First Dosing in Phase I Trial; Caldera Therapeutics Raises $112.5M\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-01-14 22:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>QYUNS-B (02509) announced that the Phase I clinical trial of its bispecific antibody, QX030N/CLD-423, which targets the clinically validated IL-23p19 and TL1A pathways, has successfully administered the first dose to healthy volunteers.\nAs of the date of this announcement, the company's partner for QX030N/CLD-423, Caldera Therapeutics, Inc., has completed a cumulative financing round totaling $112.5 million.\nIn April 2025, Caldera Therapeutics secured a $75 million Series A financing from Atlas Venture, LAV, and venBio, and recently completed a $37.5 million Series A-1 round led by Omega Funds, with participation from new investors including Wellington Management and Janus Henderson Investors.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02509","symbol_name":"荃信生物-B","start_time":0,"source_url":"","article_id":"1143628481","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1143628481","pubTimestamp":1768401499,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"QYUNS-B (02509) announced that the Phase I clinical trial of its bispecific antibody, QX030N/CLD-423, which targets the clinically validated IL-23p19 and TL1A pathways, has successfully administered...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02509":"荃信生物-B","BK1161":"生物科技"},"translate_title":"QYUNS-B(02509)：QX030N/CLD-423在I期试验中完成首次给药；Caldera Therapeutics筹集1.125亿美元","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02509":1},"content_text":"QYUNS-B (02509) announced that the Phase I clinical trial of its bispecific antibody, QX030N/CLD-423, which targets the clinically validated IL-23p19 and TL1A pathways, has successfully administered the first dose to healthy volunteers.\nAs of the date of this announcement, the company's partner for QX030N/CLD-423, Caldera Therapeutics, Inc., has completed a cumulative financing round totaling $112.5 million.\nIn April 2025, Caldera Therapeutics secured a $75 million Series A financing from Atlas Venture, LAV, and venBio, and recently completed a $37.5 million Series A-1 round led by Omega Funds, with participation from new investors including Wellington Management and Janus Henderson Investors.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1143628481","isCrawlerRequest":true}